{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:43:38Z","timestamp":1792478618258,"version":"4.5.0"},"reference-count":16,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15894","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:31:29Z","timestamp":1790937089000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["Ivonescimab combined with radiotherapy in the treatment of advanced lung adenocarcinoma with high expression of PD\u2011L1: A case report"],"prefix":"10.3892","volume":"32","author":[{"given":"Qi","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Qinghai University, Xining, Qinghai 810000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Qinghai University, Xining, Qinghai 810000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Qinghai University, Xining, Qinghai 810000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Qinghai University, Xining, Qinghai 810000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Qinghai University, Xining, Qinghai 810000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"key20261020093326_b1-ol-32-5-15894","doi-asserted-by":"publisher","first-page":"102693","DOI":"10.1016\/j.canep.2024.102693","article-title":"Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN","volume":"93","author":"Zhou","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"key20261020093326_b2-ol-32-5-15894","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/ONCO.13524","article-title":"Phase I\/II study of cisplatin plus Nab-paclitaxel with concurrent thoracic radiotherapy for patients with locally advanced non-small cell lung cancer","volume":"26","author":"Hayashi","year":"2021","journal-title":"Oncologist"},{"key":"key20261020093326_b3-ol-32-5-15894","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40265-024-02033-4","article-title":"Ivonescimab: First approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"key20261020093326_b4-ol-32-5-15894","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): A randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"key20261020093326_b5-ol-32-5-15894","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.21037\/tlcr-2024-1053","article-title":"Ivonescimab plus chemotherapy in advanced or metastatic non-squamous non-small cell lung cancer with EGFR variant in China: A cost-effectiveness analysis","volume":"14","author":"Long","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"key20261020093326_b6-ol-32-5-15894","first-page":"e77381","article-title":"Efficacy and safety of ivonescimab in the treatment of advanced non-small cell lung cancer (NSCLC): A systematic review","volume":"17","author":"Al Matairi","year":"2025","journal-title":"Cureus"},{"key":"key20261020093326_b7-ol-32-5-15894","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ajem.2018.01.008","article-title":"A systematic review of the pain scales in adults: Which to use?","volume":"36","author":"Karcioglu","year":"2018","journal-title":"Am J Emerg Med"},{"key":"key20261020093326_b8-ol-32-5-15894","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"key20261020093326_b9-ol-32-5-15894","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","article-title":"The eighth edition lung cancer stage classification","volume":"151","author":"Detterbeck","year":"2017","journal-title":"Chest"},{"key":"key20261020093326_b10-ol-32-5-15894","first-page":"39","article-title":"National Quality Control Center for Cancer: Chinese expert consensus on the combination of immune checkpoint inhibitors and radiotherapy for lung cancer (2025 edition)","volume":"47","author":"Multidisciplinary Committee on Oncology, Chinese Medical Doctor Association; Expert Committee on Quality Control of Lung Cancer","year":"2025","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"key20261020093326_b11-ol-32-5-15894","doi-asserted-by":"publisher","first-page":"e70402","DOI":"10.1002\/cam4.70402","article-title":"Combination Immunotherapy with radiotherapy in non-small cell lung cancer: A review of evidence","volume":"13","author":"Burr","year":"2024","journal-title":"Cancer Med"},{"key":"key20261020093326_b12-ol-32-5-15894","doi-asserted-by":"publisher","first-page":"1652515","DOI":"10.3389\/fonc.2025.1652515","article-title":"Remarkable response to pembrolizumab in PD-L1 overexpressing (\u2265 50%) NSCLC and extracranial abscopal effect induced by brain radiotherapy: A case report","volume":"15","author":"Xia","year":"2025","journal-title":"Front Oncol"},{"key":"key20261020093326_b13-ol-32-5-15894","doi-asserted-by":"publisher","first-page":"102785","DOI":"10.1016\/j.dnarep.2020.102785","article-title":"Cancer type-dependent correlations between TP53 mutations and antitumor immunity","volume":"88","author":"Li","year":"2020","journal-title":"DNA Repair (Amst)"},{"key":"key20261020093326_b14-ol-32-5-15894","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.molcel.2022.12.023","article-title":"p53 engages the cGAS\/STING cytosolic DNA sensing pathway for tumor suppression","volume":"83","author":"Ghosh","year":"2023","journal-title":"Mol Cell"},{"key":"key20261020093326_b15-ol-32-5-15894","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.cllc.2023.12.004","article-title":"Prognostic impact of TP53 mutations in metastatic nonsquamous non-small-cell lung cancer","volume":"25","author":"Mathiot","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"key20261020093326_b16-ol-32-5-15894","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jtho.2023.12.015","article-title":"Outcome of first-line treatment with pembrolizumab according to KRAS\/TP53 mutational status for nonsquamous programmed death-ligand 1-high (\u226550%) NSCLC in the German national network genomic medicine lung cancer","volume":"19","author":"Bischoff","year":"2024","journal-title":"J Thorac Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:33:32Z","timestamp":1792478012000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":16,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10,2]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15894","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]}}}